FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001646586> ?p ?o ?g. }

• W2001646586 endingPage "3261" @default.
• W2001646586 startingPage "3249" @default.
• W2001646586 abstract "Abstract Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The aim of NC is a pathological complete response (pCR) in the breast and axillary lymph nodes, which is the best predictor of improved outcome and prolonged survival. The taxanes docetaxel and paclitaxel are potent agents in breast cancer management, with promising single-agent activity and acceptable tolerability in the neoadjuvant setting. In this review of the taxanes as NC for operable and inoperable breast cancer, we include all fully published Phase II-III studies enrolling ≥30 patients. Current evidence suggests that the sequential administration of taxane- and anthracycline-based therapy may be superior to concomitant administration. Indeed, until the recent Phase III Aberdeen study (n = 162), it was uncertain whether NC could prolong survival. In this study, sequential docetaxel after anthracycline-based NC significantly enhanced the clinical response rate and pathological complete response, and yielded a significant 3-year survival advantage, versus anthracycline-based NC alone. Recently, the Phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B27 trial (n = 2411) showed that sequential docetaxel after doxorubicin-cyclophosphamide significantly increased both clinical and pathological response rates for operable breast cancer, with the benefit evident in both estrogen receptor-positive and estrogen receptor-negative patients. This apparent superiority of a sequential anthracycline-taxane regimen is limited to docetaxel, with no similar Phase III trials of paclitaxel versus a non-taxane-based comparator having been conducted to date. In conclusion, current evidence supports the inclusion of a taxane in NC schedules for patients with large and locally advanced breast cancer." @default.
• W2001646586 created "2016-06-24" @default.
• W2001646586 creator A5062581318 @default.
• W2001646586 creator A5085028425 @default.
• W2001646586 date "2004-05-15" @default.
• W2001646586 modified "2023-10-16" @default.
• W2001646586 title "Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer" @default.
• W2001646586 cites W1497080962 @default.
• W2001646586 cites W168674256 @default.
• W2001646586 cites W1777215171 @default.
• W2001646586 cites W1820276215 @default.
• W2001646586 cites W1892756525 @default.
• W2001646586 cites W1932878073 @default.
• W2001646586 cites W1948389446 @default.
• W2001646586 cites W1949597673 @default.
• W2001646586 cites W1970942846 @default.
• W2001646586 cites W1978291661 @default.
• W2001646586 cites W1985829224 @default.
• W2001646586 cites W1986292173 @default.
• W2001646586 cites W1989655283 @default.
• W2001646586 cites W2000009059 @default.
• W2001646586 cites W2013920437 @default.
• W2001646586 cites W2022915103 @default.
• W2001646586 cites W2025129217 @default.
• W2001646586 cites W2025689023 @default.
• W2001646586 cites W2025959372 @default.
• W2001646586 cites W2043061492 @default.
• W2001646586 cites W2045862609 @default.
• W2001646586 cites W2055679225 @default.
• W2001646586 cites W2059539152 @default.
• W2001646586 cites W2061279941 @default.
• W2001646586 cites W2069878819 @default.
• W2001646586 cites W2077209416 @default.
• W2001646586 cites W2077653876 @default.
• W2001646586 cites W2096301110 @default.
• W2001646586 cites W2096602429 @default.
• W2001646586 cites W2097110957 @default.
• W2001646586 cites W2107577958 @default.
• W2001646586 cites W2116237162 @default.
• W2001646586 cites W2122133674 @default.
• W2001646586 cites W2133764807 @default.
• W2001646586 cites W2139510434 @default.
• W2001646586 cites W2141056749 @default.
• W2001646586 cites W2142495011 @default.
• W2001646586 cites W2143321586 @default.
• W2001646586 cites W2151809511 @default.
• W2001646586 cites W2162760540 @default.
• W2001646586 cites W2245071643 @default.
• W2001646586 cites W2248496925 @default.
• W2001646586 cites W2287271371 @default.
• W2001646586 cites W2322160776 @default.
• W2001646586 cites W4233358210 @default.
• W2001646586 cites W4294413353 @default.
• W2001646586 doi "https://doi.org/10.1158/1078-0432.ccr-03-0133" @default.
• W2001646586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15161677" @default.
• W2001646586 hasPublicationYear "2004" @default.
• W2001646586 type Work @default.
• W2001646586 sameAs 2001646586 @default.
• W2001646586 citedByCount "83" @default.
• W2001646586 countsByYear W20016465862012 @default.
• W2001646586 countsByYear W20016465862013 @default.
• W2001646586 countsByYear W20016465862014 @default.
• W2001646586 countsByYear W20016465862015 @default.
• W2001646586 countsByYear W20016465862016 @default.
• W2001646586 countsByYear W20016465862017 @default.
• W2001646586 countsByYear W20016465862018 @default.
• W2001646586 countsByYear W20016465862019 @default.
• W2001646586 countsByYear W20016465862020 @default.
• W2001646586 countsByYear W20016465862021 @default.
• W2001646586 countsByYear W20016465862023 @default.
• W2001646586 crossrefType "journal-article" @default.
• W2001646586 hasAuthorship W2001646586A5062581318 @default.
• W2001646586 hasAuthorship W2001646586A5085028425 @default.
• W2001646586 hasConcept C121608353 @default.
• W2001646586 hasConcept C126322002 @default.
• W2001646586 hasConcept C143998085 @default.
• W2001646586 hasConcept C2776694085 @default.
• W2001646586 hasConcept C2776802502 @default.
• W2001646586 hasConcept C2777511904 @default.
• W2001646586 hasConcept C2778292576 @default.
• W2001646586 hasConcept C2781190966 @default.
• W2001646586 hasConcept C2781413609 @default.
• W2001646586 hasConcept C530470458 @default.
• W2001646586 hasConcept C71924100 @default.
• W2001646586 hasConceptScore W2001646586C121608353 @default.
• W2001646586 hasConceptScore W2001646586C126322002 @default.
• W2001646586 hasConceptScore W2001646586C143998085 @default.
• W2001646586 hasConceptScore W2001646586C2776694085 @default.
• W2001646586 hasConceptScore W2001646586C2776802502 @default.
• W2001646586 hasConceptScore W2001646586C2777511904 @default.
• W2001646586 hasConceptScore W2001646586C2778292576 @default.
• W2001646586 hasConceptScore W2001646586C2781190966 @default.
• W2001646586 hasConceptScore W2001646586C2781413609 @default.
• W2001646586 hasConceptScore W2001646586C530470458 @default.
• W2001646586 hasConceptScore W2001646586C71924100 @default.
• W2001646586 hasIssue "10" @default.
• W2001646586 hasLocation W20016465861 @default.
• W2001646586 hasLocation W20016465862 @default.

• next